Product Name: Recombinant Human TGF-β1

Catalog #: PCH2537



Summary

Name TGF-β1

Purity Greater than 98% as determined by reducing SDS-PAGE

Endotoxin level ≤10 EU/mg

Construction Recombinant Human TGF-β1 is produced by our Mammalian cell expression

system and the target gene encoding Ala279-Ser390 is expressed.

Accession # P01137

Host Human Cells

Species Human

Predicted Molecular Mass 12.8 kDa

Formulation Lyophilized From 0.085% TFA,30% ACN,5% mannitol,pH 2.5

Shipping The product is shipped on dry ice/polar packs.Upon receipt, store it immediately

at the temperature listed below.

Stability&Storage Store at \leq -70°C, stable for 6 months after receipt.Store at \leq -70°C, stable for 3

months under sterile conditions after opening. Please minimize freeze-thaw


cycles

Reconstitution Always centrifuge tubes before opening.Do not mix by vortex or pipetting.It is not

recommended to reconstitute to a concentration less than 100µg/ml.Dissolve the lyophilized protein in distilled water.Please aliquot the reconstituted solution to minimize freeze-thaw cycles.Always centrifuge tubes before opening.Do not mix by vortex or pipetting.It is not recommended to reconstitute to a concentration less than 100µg/ml.Dissolve the lyophilized protein in distilled water.Please

aliquot the reconstituted solution to minimize freeze-thaw cycles.

SDS-PAGE image



Background

Product Name: Recombinant Human TGF-β1

Catalog #: PCH2537



Alternative Names

Background

Transforming Growth Factor Beta-1; TGF-Beta-1; Latency-Associated Peptide; LAP; TGFB1; TGFB

Transforming Growth Factor β-1 (TGFβ-1) is a secreted protein which belongs to the TGF- β family. TGF β -1 is abundantly expressed in bone, articular cartilage and chondrocytes and is increased in osteoarthritis (OA). TGFβ-1 performs many cellular functions, including the control of cell growth, cell proliferation, cell differentiation and apoptosis. The precursor is cleaved into a latency-associated peptide (LAP) and a mature TGFβ-1 peptide.Disulfide-linked homodimers of LAP and TGF-beta 1 remain non-covalently associated after secretion, forming the small latent TGF-beta 1 complex. Purified LAP is also capable of associating with active TGF-beta with high affinity, and can neutralize TGF-beta activity. Covalent linkage of LAP to one of three latent TGF-beta binding proteins (LTBPs) creates a large latent complex that may interact with the extracellular matrix. TGF-beta activation from latency is controlled both spatially and temporally, by multiple pathways that include actions of proteases such as plasmin and MMP9, and/or by thrombospondin 1 or selected integrins. Although different isoforms of TGF-beta are naturally associated with their own distinct LAPs, the TGF-beta 1 LAP is capable of complexing with, and inactivating, all other human TGF-beta isoforms and those of most other species. Mutations within the LAP are associated with Camurati-Engelmann disease, a rare sclerosing bone dysplasia characterized by inappropriate presence of active TGF-beta 1.

Note

For Research Use Only, Not for Diagnostic Use.

Web: https://www.enkilife.com E-mail: order@enkilife.com techsupport@enkilife.com Tel: 0086-27-87002838